Table 4. Response to induction therapy... | American Society of Hematology

Table 4.

Response to induction therapy according to cytogenetic abnormalities

Cytogenetic abnormality	No. of patients	CR, %	95% CI	ED/HD, %	RD, %
Normal karyotype	161	52	44-60	11	37
Unbalanced*
+4	5	40	11-77	20	40
-5/del(5q)	54	7	3-18	26	67
-5	16	0	0-19	38	63
del(5q)	38	11	5-27	21	68
-7/del(7q)	49	6	2-17	18	76
-7	22	9	3-28	18	73
del(7q)	27	4	0-20	19	78
+8	38	32	19-47	26	42
Noncomplex	19	53	32-73	16	32
Complex	19	11	3-31	37	53
+11	20	30	12-49	30	40
Noncomplex	6	83	38-99	0	17
Complex	14	7	0-31	43	50
+13	17	18	6-41	24	59
del(13q)	14	0	0-22	21	79
+14	9	22	6-55	22	56
-17/del(17p)	24	4	0-20	29	67
-17	14	0	0-22	21	79
del(17p)	9	11	0-43	33	56
-18	9	0	0-30	33	67
-20/del(20q)	19	0	0-17	21	79
-20	7	0	0-35	29	71
del(20q)	12	0	0-24	17	83
+21	16	19	7-43	13	69
+22	14	14	4-40	14	71
Balanced†
t(8;21)	12	58	32-81	17	25
t(11q23)	11	55	28-79	18	27
t(15;17)	11	73	43-90	27	0
inv(16)/t(16;16)	14	86	60-96	14	0
Other‡
abn(3q)	14	0	0-22	14	86
abn(12p)	22	18	7-39	23	59
Complex
3 or more unrelated	61	10	5-20	28	62
5 or more unrelated	44	7	2-18	25	68
All patients	861	43	38-48	14	43

Cytogenetic abnormality	No. of patients	CR, %	95% CI	ED/HD, %	RD, %
Normal karyotype	161	52	44-60	11	37
Unbalanced*
+4	5	40	11-77	20	40
-5/del(5q)	54	7	3-18	26	67
-5	16	0	0-19	38	63
del(5q)	38	11	5-27	21	68
-7/del(7q)	49	6	2-17	18	76
-7	22	9	3-28	18	73
del(7q)	27	4	0-20	19	78
+8	38	32	19-47	26	42
Noncomplex	19	53	32-73	16	32
Complex	19	11	3-31	37	53
+11	20	30	12-49	30	40
Noncomplex	6	83	38-99	0	17
Complex	14	7	0-31	43	50
+13	17	18	6-41	24	59
del(13q)	14	0	0-22	21	79
+14	9	22	6-55	22	56
-17/del(17p)	24	4	0-20	29	67
-17	14	0	0-22	21	79
del(17p)	9	11	0-43	33	56
-18	9	0	0-30	33	67
-20/del(20q)	19	0	0-17	21	79
-20	7	0	0-35	29	71
del(20q)	12	0	0-24	17	83
+21	16	19	7-43	13	69
+22	14	14	4-40	14	71
Balanced†
t(8;21)	12	58	32-81	17	25
t(11q23)	11	55	28-79	18	27
t(15;17)	11	73	43-90	27	0
inv(16)/t(16;16)	14	86	60-96	14	0
Other‡
abn(3q)	14	0	0-22	14	86
abn(12p)	22	18	7-39	23	59
Complex
3 or more unrelated	61	10	5-20	28	62
5 or more unrelated	44	7	2-18	25	68
All patients	861	43	38-48	14	43

Patients may be counted more than once due to the coexistence of more than 1 cytogenetic abnormality in the leukemic clone. Percentages may not add to 100 because of rounding.

In the absence of t(8;21), t(11q23), t(15;17), or inv(16)/t(16;16).

†

Irrespective of karyotype complexity.

‡

Including cases with unbalanced or balanced abnormalities.

View Large

This Feature Is Available To Subscribers Only